Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Abroad (travel likely)
RecruitingPHASE1, PHASE2

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Conditions

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult · Cervical Cancer · Colorectal Cancer · Esophageal Cancer · Esophageal Squamous Cell Carcinoma · Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Head and Neck Squamous Cell Carcinoma · Melanoma · Merkel Cell Carcinoma · Microsatellite Instability-High Solid Malignant Tumor · Mismatch Repair Deficient Solid Malignant Tumor · Microsatellite Instability-High Colorectal Cancer · Mismatch Repair Deficient Colorectal Cancer · Non-small Cell Lung Cancer · Renal Cell Carcinoma · Small Cell Lung Cancer · Squamous Cell Carcinoma · Urothelial Carcinoma

Locations
  • Precision NextGen Oncology, Beverly Hills, California, United States
  • OPN Healthcare, Inc, Glendale, California, United States
  • University of Southern California, Los Angeles, California, United States
  • Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Baylor, Scott and White Research Institute, Dallas, Texas, United States
  • Northwest Medical Specialties, Tacoma, Washington, United States